ãè¥è ã®æªæ¥ããå®ãããšããªã人ãã¡ãåœãåãããŠãããšããäºå®
2025幎5æ21æ¥ã«ãã¢ã¡ãªã«ã§äžé¢åžžèšèª¿æ»å°å§å¡äŒïŒPSIïŒãéãããŸãããããã§å ¬éãããã³ããã¯ã¯ãã³ã«é¢ããäžéå ±åæžã«ã¯ãã³ããã¯ã¯ãã³æ¥çš®åŸãè¥è ã«å¿ççãçºçããŠããäºäŸãã©ã®ããã«å ±åãããããã«å¯ŸããŠæ¿åºãã©ã®ããã«å¯Ÿå¿ããããè©³çŽ°ã«æžãããŠããŸããããªãæ©æã«å¿ççã«é¢ããå ±åããã£ãã®ã«ãã¢ã¡ãªã«ã§ã¯é©åãªå¯Ÿå¿ããªãããªãã£ãããšãææãããŸãããæ¥æ¬ã§ã¯ããã®ãããªæ€èšŒãããããŠããŸããããé©åã«å¯Ÿå¿ããªãã£ãããšã¯åãã§ããããããã¢ã¡ãªã«ããã察å¿ãæªãã§ããããä»ãåœãåãããŠããæ¿æ²»å®¶ãã¡ã«ãšã£ãŠãè¥è ã®åœãæªæ¥ãã倧åãªãã®ãšã¯äœãªã®ã§ããããã
ç±³åœäžé¢åžžèšèª¿æ»å°å§å¡äŒïŒPSIïŒã§ã®äžéå ±å
54ããŒãžã«æž¡ãå ±åæžãèšå€§ãªè³æãåœæ¥ã®åç»ã¯ãäžèšã®ãµã€ãã§å ¬éãããŠããŸãã
å ±åæžã2025.05.21 â PSI Majority Staff Interim Report â Failure to Warn
é·ãã®ã§ããã€ã³ãã ãæŸã£ãŠãããŸãã
6ããŒãž

ã»CDCã®è·å¡ã¯ã2021幎2æãšããæ©ãææã«ãCOVID-19ã¯ã¯ãã³æ¥çš®åŸã®è¥å¹Žæäººã«ãããå¿ççã«é¢ããå ±åãåãå§ããŠããã
ã»2021幎5æãŸã§ã«ãHHSã®ä¿å¥åœå±ã¯å¿ççã®ãªã¹ã¯ã«é¢ããæ£åŒãªèŠåãçºä»€ãããã©ãããè°è«ããã
ã»å¿ççã«é¢ããæ£åŒãªèŠåã¯ãå¥åº·èŠå ±ãããã¯ãŒã¯ïŒHANïŒã¡ãã»ãŒãžãšããŠå
šåœã«é
ä¿¡ãããäºå®ã ã£ãã
ãšãããã»ã»ã»
ã»CDCãšFDAã¯æçµçã«æ£åŒãªHANãçºè¡ããªãããšã決å®ãã代ããã«CDCã®ãŠã§ããµã€ãã«å¿ççã«é¢ãããèšåºäžã®èæ ®äºé ããæ²èŒããã
æ£åŒãªèŠåãšããŠçºä¿¡ãããWebãµã€ãã«æ²èŒããŠããã ãã§ã¯ãæ¢ãã人ãèŠãã ãã§ãå€ãã®äººã«ç¥ãããããšãã§ããŸããã
å ±åæžã§ã¯ãã®åŸãæç³»åã§ ãã€ãã³æ¿æš©ã«ããã³ããã¯ã¯ãã³æ¥çš®åŸã®å¿ççã®ãªã¹ã¯ã«å¯Ÿããèªèãšå¯Ÿå¿ãæžãããŠããŸãããããã®èšé²ã¯ããã€ãã³æ¿æš©ãå¿ççã®ãªã¹ã¯ã«ã€ããŠåœæ°ãžã®èŠåã軜èŠããé ãããããšããŠããããšã瀺ããŠããŸãããã¡ãŒã«ã®ãããšããªã©ãã詳现ã«èšãããŠããŸãã
以äžãäžäŸã§ãã

2021幎2æ26æ¥
2æ22æ¥ã«è¡ã£ãé»è©±äŒè°ã®è°äºé²ãã
ã»VAERSãžã®å ±åã¯ã¢ãã«ã瀟ã7,092ä»¶ããã¡ã€ã¶ãŒã»ããªã³ããã¯ç€Ÿã12,444ä»¶ãããã¯ã¯ãã³æ¥çš®åŸã®COVID-19çºçå ±åã¯1,287ä»¶ãæ»äº¡å ±åã¯980ä»¶ã
ã»æ»äº¡å ±åã®ãã¡470ä»¶ã¯é·æç逿œèšããã®ãã®ã
ã»æ»å ã倿ããŠããå Žåãå¿è¡ç®¡çŸæ£ã§ããããšãã»ãšãã©ã ã£ãã
PSI Failure to Warn Supporting Documents â Part 11

ãVAERSãã«ã€ããŠã¯ãååŽçã®è³æã«èª¬æããããŸãã
第57ååçç§åŠå¯©è°äŒäºé²æ¥çš®ã»ã¯ã¯ãã³åç§äŒå¯åå¿æ€èšéšäŒ
ç±³åœã®äºé²æ¥çš®å®å
šæ§ç£èŠã·ã¹ãã ã«ã€ããŠ

ã§ããããå ±åããã¹ãŠã¯ã¯ãã³æ¥çš®ãšé¢ä¿ããããšããããšã§ã¯ãããŸãããããã©ãã調æ»ã®äžå¿ãšãªã£ããã³ã»ãžã§ã³ãœã³äžé¢è°å¡ã¯äžèšã®ãããªæžç°¡ãäœåºŠãéã£ãŠããŸããã
51ããŒãž

ãžã§ã³ãœã³äžé¢è°å¡ã¯2021幎8æ22æ¥ä»ã®NIHãCDCãFDAå®ãŠã®æžç°¡ã§ãVAERSã«å¯ããããå ±åã«ã€ããŠäžèšã®ããã«èšããŠããŸãã
ã»2021幎8æ20æ¥çŸåšãVAERSã«ã¯COVID-19ã¯ã¯ãã³ã«é¢é£ããŠãäžçäžã§12,791äººã®æ»äº¡ã®å ±åãããã
ã»ãããã®æ»äº¡ã®ãã¡ã4,632人ã¯ã¯ã¯ãã³æ¥çš®åŸ0æ¥ç®ã1æ¥ç®ããŸãã¯2æ¥ç®ã«çºçã
ã»CDCãšFDAãææããããã«ãVAERSã®å ±åã¯å æé¢ä¿ã蚌æãããã®ã§ã¯ãªãããããããã®æ»äº¡æ°ãç¹ã«36.2%ãã¯ã¯ãã³æ¥çš®åŸ2æ¥ä»¥å
ã«çºçããŠããããšã¯ãæ·±å»ãªæžå¿µãšãšãããã¹ãã ã
ã»8ãæéã«VAERSã«å ±åãããCOVID-19ã¯ã¯ãã³é¢é£ã®æ»äº¡è
æ°ã12,791人ã§ããããšã¯ãéå»31幎éã«æž¡ãä»ã®ãã¹ãŠã®ã¯ã¯ãã³é¢é£ã®æ»äº¡è
æ°8,966äººãšæ¯èŒããŠããæ³šç®ãã¹ãã ã
äžèšã¯åœæ¥ïŒåç»ããïŒç€ºãããã¯ã¯ãã³é¢é£æ»ã®ã°ã©ãã§ãããèµ€ãã³ããã¯ã¯ãã³ãéãä»ã®å šãŠã®ã¯ã¯ãã³ã®åèšã2021幎ã®ç°åžžããäžç®çç¶ã§ãã

æ¥æ¬ã§ã¯ã2021幎7æå ¬éã®åç»ã§å ã¯ã¯ãã³æ åœå€§è£ããäžèšã®ãããªçºèšãããŠããŸããã
å ã®åç»ïŒ2021幎7æ2æ¥å ¬éïŒã¯éå ¬éã«ãªã£ãŠããŸããŸããããäžèšã®èšäºããã¹ã¯ã·ã§ãæãèµ·ãããŸããã

6ïŒ50é
2åæã£ãŠ2é±éããããããªãå®ãããŠãããšæã£ãŠãããå¹æã¯æå¹ç95ïŒ ã§ããã ããçžåœå¹æããããŸããã
ããããªåœã®æ§åãã¿ãŠãããšããã¶ãçºçããªããšãéçåããªããšãã ãã§ãªãããã¶ãã¯ã¯ãã³æã£ããææããªããšããããšæãã
ãŸãèªåãããããªããã人ã«ãã€ãããšããªããåšãã®äººãå®ãããšã«ããªãããè¥ã人ã«ãæã£ãŠã»ããã
ãææããªãããšããåšãã®äººãå®ãããªã©ãæ·»ä»ææžã«æžãããŠããªãããšãŸã§èšã£ãŠããŸãããã2æã®æç¹ã§ãåè¿°ã®ãšããVAERSã«ã¯ã¯ãã³æ¥çš®åŸã®COVID-19çºçå ±åã1,287ä»¶ãã£ãã®ã«ãããã¶ãã¯ã¯ãã³æã£ããææããªããšããããšæãããªã©ãšã©ãããŠèšããã®ã§ããããã
ããã«ãã¯ã¯ãã³æ åœå€§è£ãªããéå»ã®è¬å®³èšŽèšããæ·»ä»ææžãéèŠããªããã°ãªããªãããšãç¥ã£ãŠãããšæãã®ã§ããããªãæ·»ä»ææžãéžè±ããããšãå¹³æ°ã§èšããã®ã§ãããããïŒäžèšåç §ïŒã
ãè¥ã人ã«ãæã£ãŠã»ããããšèšã£ãŠããŸãããã2021幎5æ28æ¥ã«CDCã¯ãŠã§ããµã€ãã«ãèšåºäžã®èæ ®äºé ããšããŠå¿ççã«ã€ããŠæ²èŒããŠããŸãã

ã¯ã¯ãã³æ åœå€§è£ãªãåœç¶ãã®æ å ±ãåŸãŠããã¯ãã§ãããã€åé²ãããããããŸããããããåé²åŸã«æ å ±ãåŸããªããå ¬éåã«åå¹çã§ä¿®æ£äŸé Œãããããšã ã£ãŠã§ããã§ããããæ¥çš®ãžã®æ³šæãåŒã³ãããã¹ãè¥è ã«ãæã£ãŠã»ããããšãããªããŠããè¥è ã®æªæ¥ããå®ãããšããæ°æã¡ãªã©ãªããšããæããŸããã
äžèšã®çºèšãèãã°ãè¥è ã ãã§ãªããæ¥æ¬åœæ°ã®åœãå®ãããã«æ¥çš®ãåŒã³ãããŠãããšã¯ããšãŠãæããŸããã

2ææç¹ã§VAERSã«ã¯æ»äº¡å ±åã980ä»¶ãã£ãã®ã§ããå æé¢ä¿ãèªããããŠãªãããšãèšããããªããã2ååæã£ãŠâ¯äººäº¡ããªã£ãŠããããã©ãå æé¢ä¿ãèªããããŠãã人ã¯ãŸã ããªãããšèšãã¹ãã ã£ãã®ã§ã¯ãªãã§ããããã
ã€ã¹ã©ãšã«ããå¿ççã«é¢ããå ±å
å ±åæžã«ã¯ãCDCãFDAã¯è¥å¹Žå±€ãå«ã¿ã¢ã¡ãªã«ããã¯ããã«å€ãã®åœæ°ã«ã¯ã¯ãã³æ¥çš®ãè¡ã£ãŠããã€ã¹ã©ãšã«ããã2021幎2æã«ã¯å¿ççã«é¢ããå ±åãåããŠããããšãèšãããŠããŸãã2æã§ãïŒ


ããã«ãé¢ããããFDAãå¿ççãšå¿èçã®ã瀺åããããªã¹ã¯å¢å ãã«åºã¥ããã¢ãã«ã瀟ãšãã¡ã€ã¶ãŒç€Ÿã®COVID-19ã¯ã¯ãã³ã®æ·»ä»ææžã倿Žãããšçºè¡šããã®ã¯2021幎6æ25æ¥ã§ããã


ãã®ãããã®ããšã¯ãäžèšã®èšäºïŒ2021幎6æ27æ¥ïŒã§ãåãäžããŸããã
æ¥æ¬ã§ã2021幎6æ28æ¥ã«éå¬ãããã第ïŒåå»è¬åçè¡æ¿è©äŸ¡ã»ç£èŠå§å¡äŒã§å¿ççã®ãªã¹ã¯ã«ã€ããŠææããŠããå§å¡ãããŸããïŒäžèšåç §ïŒã
èšäºããäžéšãæç²ããŸãã
âäœè€å§å¡ ãå æ¥ã®å¯åå¿éšäŒãæ€èšéšäŒã®ããšã«é¢ããŠãªã®ã§ãããå¿ççã®ããšã倧åããªãè°è«ãããŠããŸããããç§ãåèŽãããŠããã ããŸããããã©ãããã®äžã§ææããã£ãã®ã¯ããã¯ãå¿ççã®ãªã¹ã¯ã«ã€ããŠãã¡ããšåšç¥ãã¹ãã§ãããšããããšãèšãããããšæããŸããç¹ã«è¥ãæ¹ãè¥ãç·æ§ããªãããããšããããšããã£ãŠãèžãèŠãããšããããããã¯ããã«å ç«ã€ãããªçç¶ããã£ããšãã«äžè¬ã®æ¹ã¯å¿ççãšããããšèªäœãç¥ããªãã®ã§ãããããããšãèµ·ããããã¯ã¯ãã³æ¥çš®åŸã«ããããå¿ççã®çç¶ãèµ·ãããããã«å»çæ©é¢ã«é£çµ¡ãããªãææ¥è»ãåŒã¶ãªããã¹ãã§ãããšããããšããã£ãšåšç¥ãããªããšæé ãã«ãªãäŸããããšããããããã埡ææã¯ãã£ããšæãã®ã§ãããã§ãã®ã§ãååŽçãäœæããŠãããã®ã¯ã¯ãã³ãæ¥çš®ããæ¹ãžãšããåèè³æïŒïŒïŒã«åºãŠããã¯ã¯ãã³æ¥çš®ã®ãç¥ããã®äžã§ãå¿ççã®ãªã¹ã¯ã«ã€ããŠãã¡ããšèšè¿°ãã¹ãã§ã¯ãªãããšæããŸããäžå¿ããã¯æèŠãšããŠç³ããŠãããŸãã
ããã«å¯ŸããŠãäžèšã®åçããããŸããã
âå±±å£äºé²æ¥çš®å®€ã¯ã¯ãã³å¯Ÿçå°éå®ã 埡ææããããšãããããŸãã
埡ææãã£ãšãã§ããããŸããŠãæã ãšããŠãç¹ã«ä»ãå¿ççã«ã€ããŠã¯è¥ãæ¹ã®æ¥çš®ãå§ãŸã£ãŠãããŸãã®ã§ãé©åãªæ å ±æäŸããŠãŸãããããšæã£ãŠãããŸããå çã®ãããªåŸ¡æèŠãå«ããŠãä»ãåãçµãã§ãããšããã§ããããŸãã埡ææããããšãããããŸãã
ãããŠã2021幎7æ13æ¥ã«ããããããæ°åã³ããã¯ã¯ãã³äºé²æ¥çš®ã«ã€ããŠã®èª¬ææžãããã¡ã€ã¶ãŒç€Ÿãã¢ãã«ã瀟ãšãã«æŽæ°ãããŸããã
ãã¡ã€ã¶ãŒç€Ÿã®èª¬ææžã

ã¢ãã«ã瀟ã®èª¬ææžã

ããã©ãã远èšãããããšã¯ããã¬ããªã©ã®ã¡ãã£ã¢ã倧ããå ±ããããšã¯ãããŸããã§ãããçããã¯ãã®ææã«ãå¿ççã®ãªã¹ã¯ã«ã€ããŠç¥ããããŠããŸãããïŒãæ¥çš®ããåã«ãå»åž«ããèããããŠããŸãããïŒ
ãªã¹ã¯ãèããããŠããããæ¥çš®ããªããšããéžæããã人ãããã§ãããã
äºé²æ¥çš®å¥åº·è¢«å®³ææžå¶åºŠã§å¿ççã«ããæ»äº¡äºäŸã倿°èªå®ãããŠããŸããããã®äººãã¡ããªã¹ã¯ãç¥ã£ãŠãããæ¥çš®ããªãã£ããããããªãã®ã§ãã
å ±åæžã®çµè«ã«ã¯ãããã€ãã³æ¿æš©ãCOVID-19ã¯ã¯ãã³ã®å¯äœçšã«ã€ããŠåœæ°ã«çŽã¡ã«èŠåããªãã£ã責任ã®å šå®¹ã¯ã培åºçã«æããã«ãããªããã°ãªããªãããšæžãããŠããŸãã
æ¥æ¬ã®æ¿åºã«ããã¯ã¯ãã³ã®å¯äœçšã«ã€ããŠåœæ°ã«çŽã¡ã«èŠåããªãã£ã責任ãããã¯ãã§ãã
åã©ããè¥è ãå®ããªãåœã«ãæªæ¥ã¯ããã®ã§ãããããåœäŒè°å¡ã¯ããã£ããäœãå®ãããã®ã§ããããã
